Carina Biotech develops next-generation CAR-T therapies to empower patients in their fight against cancer by enhancing the specificity and efficacy of T-cell responses. The company focuses on pre-clinical research to address the limitations of current immunotherapy options, aiming to improve patient outcomes in oncology.
Funding
$12.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR-T therapies face limitations in specificity and efficacy, leading to suboptimal outcomes for cancer patients. The challenges include off-target effects, limited penetration into solid tumors, and T-cell exhaustion, which can hinder the ability of CAR-T cells to effectively target and eliminate cancer cells.
Solution
Carina Biotech is developing next-generation CAR-T cell therapies designed to enhance the precision and potency of T-cell responses against cancer. Their approach focuses on overcoming the limitations of existing immunotherapies by improving CAR-T cell specificity to minimize off-target effects and increasing their ability to infiltrate and eradicate solid tumors. By engineering CAR-T cells with enhanced functionality and persistence, Carina Biotech aims to deliver more effective and durable anti-cancer responses, ultimately improving patient outcomes in oncology.
Target Audience
The primary target audience includes cancer patients who are not adequately responding to existing therapies, as well as oncologists and hematologists seeking more effective and targeted treatment options.
Features
- Enhanced CAR-T cell specificity to reduce off-target effects on healthy tissues
- Improved tumor penetration capabilities for effective targeting of solid tumors
- Engineered T-cells with increased persistence to provide durable anti-cancer responses
- Pre-clinical research focused on optimizing CAR-T cell design and functionality